Pathstone Holdings
CTSO icon

Pathstone Holdings’s Cytosorbents Corp CTSO Stock Holding History

Pathstone Holdings’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Hold
499,955
– – ﹤0.01% 1997
2025
Q4 		$320K Buy
+499,955
New +$385K ﹤0.01% 1932

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM

Pathstone Holdings's CTSO Position: Q1 2026 in Review

Pathstone Holdings held its Cytosorbents Corp (CTSO) position steady in Q1 2026 at 499,955 shares worth $283K. The position accounts for ﹤0.01% of the portfolio, ranked #1997.

Pathstone Holdings first reported a position in CTSO in Q4 2025 and has held it in 2 quarters since. The position peaked at $320K in Q4 2025. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • Pathstone Holdings held 499,955 shares of Cytosorbents Corp worth $283K as of Q1 2026.
  • Pathstone Holdings left its Cytosorbents Corp share count unchanged in Q1 2026.
  • Cytosorbents Corp made up ﹤0.01% of Pathstone Holdings's portfolio in Q1 2026, its #1997 holding.
  • Pathstone Holdings first reported a position in Cytosorbents Corp in Q4 2025 and has held it in 2 quarters since.
  • Pathstone Holdings's Cytosorbents Corp position peaked at $320K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.